Improving the recognition and management of acromegaly
Activity Description / Statement of Need:
In this online, self-learning activity:
Acromegaly is an endocrine disorder characterized by dysregulated hypersecretion of growth hormone (GH), usually caused by a GH-secreting, pituitary adenoma and leading to an overproduction of insulin-like growth factor 1 (IGF-1). Estimated at between 40 and 240 people per million, is not as high as other endocrine disorders, acromegaly has a significant impact on patient quality of life. Approximately 25 percent of people with acromegaly have elevated blood pressure, and 50 percent have evidence of insulin resistance, putting them at risk of developing type 2 diabetes in future. The mortality rates of acromegaly patients are three times higher than the general population, with most dying from respiratory or cardiac complications.
Target Audience:
HCPs including: endocrinologists and primary care providers; physician assistants, nurse practitioners, and pharmacists who specialize in endocrinology; and any other healthcare professionals with an interest in or who clinically encounter patients with acromegaly.
Cost: Free
View Offer chevron_rightDetails
Activity Description / Statement of Need:
In this online, self-learning activity:
Acromegaly is an endocrine disorder characterized by dysregulated hypersecretion of growth hormone (GH), usually caused by a GH-secreting, pituitary adenoma and leading to an overproduction of insulin-like growth factor 1 (IGF-1). Estimated at between 40 and 240 people per million, is not as high as other endocrine disorders, acromegaly has a significant impact on patient quality of life. Approximately 25 percent of people with acromegaly have elevated blood pressure, and 50 percent have evidence of insulin resistance, putting them at risk of developing type 2 diabetes in future. The mortality rates of acromegaly patients are three times higher than the general population, with most dying from respiratory or cardiac complications.
Target Audience:
HCPs including: endocrinologists and primary care providers; physician assistants, nurse practitioners, and pharmacists who specialize in endocrinology; and any other healthcare professionals with an interest in or who clinically encounter patients with acromegaly.